arrow
G

Giacomo Musso

vita salute san-raffaele university
H指数:12
被引数:1,407

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials

辅助性帕博利珠单抗联合belzutifan与安慰剂在透明细胞肾细胞癌中的比较:KEYNOTE-564和LITESPARK-022试验的重建生存数据分析

2026-09-110
OAAI
First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL-PNRR-POC-2023-12377493)

首次人体外研究验证碳酸酐酶IX-PET在高风险肾癌中的应用(CAT-VHL-PNRR-POC-2023-12377493)

2026-05-180
PRE
A STEP FORWARD IN RCC STAGING: EXTERNAL VALIDATION OF THE EAU-PROPOSED M STAGING

肾细胞癌分期的一大步:对欧洲泌尿外科学会(EAU)提议的M分期的外部验证

2026-05-010
PRE
OUTCOMES OF KIDNEY-SPARING VERSUS RADICAL NEPHROURETERECTOMY FOR HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA: RESULTS FROM THE ROBUUST REGISTRY

保留肾脏与根治性肾输尿管切除术治疗高级别上尿路尿路上皮癌的结局:ROBUUST登记研究的结果

2026-05-010
PRE
SINGLE-PORT VERSUS MULTI-PORT ROBOTIC NEPHROURETERECTOMY: A MULTI-INSTITUTIONAL CONTEMPORARY COMPARISON OF PERIOPERATIVE OUTCOMES AND TETRAFECTA ACHIEVEMENT FROM THE ROBUUST AND SPARC COLLABORATIVE GROUPS

单孔与多孔机器人肾盂输尿管切除术:ROBUUST和SPARC协作组多中心当代比较 perioperative outcomes 和 Tetrafeca 实现

2026-05-010
PRE
COMPARATIVE PROGNOSTIC PERFORMANCE OF KEYNOTE-564 AND AUA RISK STRATIFICATION IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA

比较KEYNOTE-564与AUA风险分层在非转移性透明细胞肾细胞癌中的预后性能

2026-05-010
PRE
DEVELOPMENT AND INTERNAL VALIDATION OF MACHINE-LEARNING MODELS TO PREDICT ADVERSE PATHOLOGICAL FEATURES IN UPPER TRACT UROTHELIAL CARCINOMA USING DATA FROM THE ROBUUST 3.0 COLLABORATIVE

基于ROBUUST 3.0协作组数据开发并内部验证用于预测上尿路尿路上皮癌不良病理特征的机器学习模型

2026-05-010
PRE
LYMPH NODE DISSECTION IN LOW GRADE UPPER TRACT UROTHELIAL CARCINOMA: A RETROSPECTIVE ANALYSIS OF THE ROBUUST 3.0 COLLABORATIVE

低级别上尿路尿路上皮癌淋巴结清扫术:ROBUUST 3.0协作组的回顾性分析

2026-05-010
PRE
NEOADJUVANT GEMCITABINE/CISPLATIN VERSUS DOSE-DENSE MVAC FOR UPPER TRACT UROTHELIAL CARCINOMA: RESULTS FROM THE MULTI-INSTITUTIONAL ROBUUST COLLABORATION

新辅助吉西他滨/顺铂与剂量密集型MVAC方案治疗上尿路尿路上皮癌的多机构ROBUUST协作研究结果

2026-05-010
PRE
ROBOTIC VS. OPEN PARTIAL NEPHRECTOMY IN COMPLEX CASES: REAL WORLD BENCHMARKING OF THE OPERA TRIAL

机器人辅助与开放性部分肾切除术在复杂病例中的比较:OPERA试验的真实世界基准评估

2026-05-010
PRE
SURGERY ON THE EDGE: REAL-WORLD OUTCOMES OF PARTIAL AND RADICAL NEPHRECTOMY IN PATIENTS WITH STAGE 4 CHRONIC KIDNEY DISEASE

手术的边缘:慢性肾病4期患者行部分肾切除术与根治性肾切除术的真实世界结局

2026-05-010
PRE
WHEN THE THROMBUS RISES: INFERIOR VENA CAVA INVOLVEMENT IMPAIRS PREOPERATIVE RENAL FUNCTION IN RENAL CELL CARCINOMA

当血栓升高:下腔静脉受累损害肾细胞癌患者的术前肾功能

2026-05-010
PRE
RENAL FUNCTIONAL FOLLOWING ANGIOEMBOLIZATION AFTER PARTIAL NEPHRECTOMY

部分肾切除术后行血管栓塞术后的肾功能

2026-05-010
PRE
PROGNOSTIC IMPLICATIONS OF NODAL STATUS IN LOCALIZED AND LOCALLY-ADVANCED RENAL CELL CARCINOMA: ANALYSIS FROM THE NCDB

淋巴结状态在局部性和局部进展性肾细胞癌中的预后意义:NCDB数据分析

2026-05-010
PRE
RANDOMIZED PILOT TRIAL OF PRE-VISIT PATIENT EDUCATION FOR PREPARATION FOR DECISION MAKING IN NEWLY DIAGNOSED PROSTATE CANCER (PREPDM)

新诊断前列腺癌患者决策准备术前患者教育的随机试点试验(PREPDM)

2026-05-010
PRE
PERSONALIZED PREDICTORS OF RENAL RECOVERY AFTER PARTIAL NEPHRECTOMY

部分肾切除术后肾功能恢复的个性化预测因子

2026-05-010
PRE
COMPARATIVE PERFORMANCE OF EUA AND AUA RISK STRATIFICATION MODELS AND DEVELOPMENT OF AN INTEGRATED MODEL FOR PREDICTING ≥PT2 UPPER TRACT UROTHELIAL CARCINOMA: A ROBUUST ANALYSIS

EUA和AUA风险分层模型的比较性能及预测≥PT2上尿路尿路上皮癌的集成模型开发:一项稳健性分析

2026-05-010
PRE
REFINING SURVEILLANCE FOR SMALL RENAL MASSES: PREDICTING AGGRESSIVENESS AND ONCOLOGIC OUTCOMES BASED ON TUMOUR SIZE AND PATIENT CHARACTERISTICS

优化小肾肿瘤的观察随访:基于肿瘤大小和患者特征预测侵袭性和肿瘤学结局

2026-05-010
PRE
POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY: STILL A REAL CONCERN OR A FADING THREAT?

部分肾切除术后的阳性手术切缘:仍然是一个真实的问题还是逐渐消失的威胁?

2026-05-010
PRE
CYTOREDUCTIVE NEPHROURETERECTOMY PLUS SYSTEMIC THERAPY VERSUS SYSTEMIC THERAPY ALONE IN METASTATIC UTUC: AN NCDB PROPENSITY-SCORE MATCHED ANALYSIS

细胞减灭性肾输尿管切除术联合全身治疗与仅全身治疗在转移性上尿路尿路上皮癌中的比较:一项NCDB倾向性评分匹配分析

2026-05-010
PRE